NRx Pharmaceuticals unit wins $11.2 million DARPA contract for depression trial
On September 29, 2026, subsidiary NRx Defense Systems entered a prime contract with DARPA to conduct the SPARC-TMS clinical trial, which pairs robotic transcranial magnetic stimulation with the investigational drug NRX-101 for treatment-resistant depression. The contract is valued at approximately $11.2 million, with about $6.7 million initially obligated, and the remainder depends on appropriations and DARPA's exercise of funding options.
Key points
- Aggregate contract value of approximately $11.2 million; approximately $6.7 million initially obligated by DARPA.
- 18-month performance period, with payment tied to achievement and acceptance of specified milestones.
- Either party may terminate under certain circumstances, including if the program is determined unlikely to achieve its objectives.
- Full contract terms to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.